Idorsia: Failure in Phase III
The Allschwil-based company announced that in its Phase III study MODIFY, lucerastat did not meet its primary endpoint in patients with Fabry...
Quell raises US$156m for Treg cell therapy programme
The financing round was co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company...
EU orders up Valneva’s inactivated Covid-19 vaccine
The European Commission has approved an agreement with Valneva under which the French vaccine maker would supply up to 60 million doses of VLA2001,...
Santhera finds Chinese marketing partner for vamorolone
Under this agreement, Sperogenix will in-license vamorolone for rare disease indications for a total consideration of up to US-$124m, including...
Sanofi acquires therapeutic acne vaccine
Privately-owned Origrimm, based in Vienna, develops a vaccine-based immunotherapy against acne. ORI-001 is potentially the first-in-class vaccine...
BioNTech SE licences Cresendo Bio’s Humabody technology
The three-year collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise including mRNA-based antibodies and cell therapies...
Depixus raises €30.6m in Series A financing
The financing of the spin-out from Paris-based Ecole Normale Supérieure (ENS) was led by Lansdowne Partners and Bpifrance with participation by...